Seminars in Radiation Oncology
Volume 17, Issue 3 , Pages 223-229 , July 2007

Primary Central Nervous System Lymphoma

  • Nimish A. Mohile, MD
    • ,
  • Lauren E. Abrey, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Lauren E. Abrey, MD, Department of Neurology, 1275 York Avenue, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

References 

  1. DeAngelis LM, Gutin PH, Leibel SA. Intracranial Tumors (Diagnosis and Treatment). (ed 1). London, UK: Martin Dunitz; 2002;
  2. Omuro AM, Ben-Porat LS, Panageas KS. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol. 2005;62:1595–1600
  3. Schabet MM. Epidemiology of primary CNS lymphoma. J Neurooncol. 1999;43:199–201
  4. Coté TR, Manns A, Hardy CR AIDS/Cancer Study Group. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. J Natl Cancer Inst. 1996;88:675–679
  5. Olson JE, Janney CA, Rao RD. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: A surveillance, epidemiology, and end results analysis. Cancer. 2002;95:1504–1510
  6. Corn BW, Marcus SM, Topham A. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000?. Cancer. 1997;79:2409–2413
  7. Eby NL, Grufferman S, Flannelly CM. Increasing incidence of primary brain lymphoma in the US. Cancer. 1988;62:2461–2465
  8. Hao D, DiFrancesco LM, Brasher PM. Is primary CNS lymphoma really becoming more common? (A population-based study of incidence, clinicopathological features and outcomes in Alberta from 1975 to 1996). Ann Oncol. 1999;10:65–70
  9. Kadan-Lottick NS, Skluzacek MC, Gurney JG. Decreasing incidence rates of primary central nervous system lymphoma. Cancer. 2002;95:193–202
  10. Ferreri AJ, Abrey LE, Blay JY. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol. 2003;21:2407–2414
  11. Shenkier TN, Blay JY, O’Neill BP. Primary CNS lymphoma of T-cell origin: A descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol. 2005;23:2233–2239
  12. Küker W, Nägele T, Korfel A. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol. 2005;72:169–177
  13. Pollack IF, Lunsford LD, Flickinger JC. Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer. 1989;63:939–947
  14. Corry J, Smith JG, Wirth A. Primary central nervous system lymphoma: Age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys. 1998;41:615–620
  15. Blay JY, Lasset C, Carrie C. Multivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma (A proposal for a prognostic scoring). Br J Cancer. 1993;67:1136–1141
  16. Ferreri AJ, Blay JY, Reni M. Prognostic scoring system for primary CNS lymphomas: The International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21:266–272
  17. Abrey LE, Ben-Porat L, Panageas KS. Primary central nervous system lymphoma: The Memorial Sloan Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24:5711–5715
  18. Mohile NA, DeAngelis LM, Abrey LE. The role of cranial and body 18 flouro-deoxyglucose positron emissiton tomography in primary CNS lymphoma. Proc Am Soc Clin Oncol. 2006;24:66s
  19. Todd FD, Miller CA, Yates AJ. Steroid-induced remission in primary malignant lymphoma of the central nervous system. Surg Neurol. 1986;26:79–84
  20. Weller M. Glucocorticoid treatment of primary CNS lymphoma. J Neurooncol. 1999;43:237–239
  21. Lai R, Rosenblum MK, DeAngelis LM. Primary CNS lymphoma: A whole-brain disease?. Neurology. 2002;59:1557–1562
  22. Shibamoto Y, Hayabuchi N, Hiratsuka J. Is whole-brain irradiation necessary for primary central nervous system lymphoma? (Patterns of recurrence after partial-brain irradiation). Cancer. 2003;97:128–133
  23. Blay JY, Conroy T, Chevreau C. High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol. 1998;16:864–871
  24. Nelson DF, Martz KL, Bonner H. Non-Hodgkin’s lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? (Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315). Int J Radiat Oncol Biol Phys. 1992;23:9–17
  25. Bessell EM, López-Guillermo A, Villá S. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: An analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol. 2002;20:231–236
  26. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: The next step. J Clin Oncol. 2000;18:3144–3150
  27. Gavrilovic IT, Hormigo A, Yahalom J. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006;24:4570–4574
  28. Yahalom J, Shah GD, Lai RK, et al. Reduced-dose whole brain radiotherapy (WBRT) following complete response to immuno-chemotherapy in patients with primary CNS lymphoma (PCNSL). Int J Rad Onc Biol Phys. 2006;66:s84;(abstr)
  29. Lachance DH, Brizel DM, Gockerman JP. Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: Short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology. 1994;44:1721–1727
  30. Schultz C, Scott C, Sherman W. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: Initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol. 1996;14:556–564
  31. Shibamoto Y, Tsutsui K, Dodo Y. Improved survival rate in primary intracranial lymphoma treated by high-dose radiation and systemic vincristine-doxorubicin-cyclophosphamide-prednisolone chemotherapy. Cancer. 1990;65:1907–1912
  32. Brada M, Dearnaley D, Horwich A. Management of primary cerebral lymphoma with initial chemotherapy: Preliminary results and comparison with patients treated with radiotherapy alone. Int J Radiat Oncol Biol Phys. 1990;18:787–792
  33. Skarin AT, Zuckerman KS, Pitman SW. High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood. 1977;50:1039–1047
  34. Ferreri AJ, Guerra E, Regazzi M. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer. 2004;90:353–358
  35. DeAngelis LM, Yahalom J, Thaler HT. Combined modality therapy for primary CNS lymphoma. J Clin Oncol. 1992;10:635–643
  36. Cheng AL, Yeh KH, Uen WC. Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: A pilot study of the BOMES protocol. Cancer. 1998;82:1946–1951
  37. Batchelor T, Carson K, O’Neill A. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07. J Clin Oncol. 2003;21:1044–1049
  38. DeAngelis LM, Seiferheld W, Schold SC. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002;20:4643–4648
  39. Ferreri AJ, Dell’Oro S, Foppoli M. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology. 2006;66:1435–1438
  40. Omuro AM, DeAngelis LM, Yahalom J. Chemoradiotherapy for primary CNS lymphoma: An intent-to-treat analysis with complete follow-up. Neurology. 2005;64:69–74
  41. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol. 2003;21:4483–4488
  42. Bessell EM, Graus F, Lopez-Guillermo A. Primary non-Hodgkin’s lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: Long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys. 2004;59:501–508
  43. Slevin ML, Piall EM, Aherne GW. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol. 1983;1:546–551
  44. Hiraga S, Arita N, Ohnishi T. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg. 1999;91:221–230
  45. Khan RB, Shi W, Thaler HT. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?. J Neurooncol. 2002;58:175–178
  46. Shapiro WR, Young DF, Mehta BM. Methotrexate: Distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. New Engl J Med. 1975;293:161–166
  47. Panageas KS, Elkin EB, DeAngelis LM. Trends in survival from primary central nervous system lymphoma, 1975-1999: A population-based analysis. Cancer. 2005;104:2466–2472
  48. Milpied N, Deconinck E, Gaillard F. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350:1287–1295
  49. Abrey LE, Moskowitz CH, Mason WP. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: An intent-to-treat analysis. J Clin Oncol. 2003;21:4151–4156
  50. Cheng T, Forsyth P, Chaudhry A. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant. 2003;31:679–685
  51. Illerhaus G, Marks R, Ihorst G. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006;24:3865–3870
  52. Neuwelt EA, Goldman DL, Dahlborg SA. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function. J Clin Oncol. 1991;9:1580–1590
  53. Guha-Thakurta N, Damek D, Pollack C. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: Response to therapy and quality of life of patients. J Neurooncol. 1999;43:259–268
  54. Arellano-Rodrigo E, López-Guillermo A, Bessell EM. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol. 2003;70:219–224
  55. Herrlinger U, Brugger W, Bamberg M. PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology. 2000;54:1707–1708
  56. Pels H, Schulz H, Schlegel U. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: Experience with two cases and review of the literature. Onkologie. 2003;26:351–354
  57. Reni M, Mason W, Zaja F. Salvage chemotherapy with temozolomide in primary CNS lymphomas: Preliminary results of a phase II trial. Eur J Cancer. 2004;40:1682–1688
  58. Soussain C, Suzan F, Hoang-Xuan K. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001;19:742–749
  59. Enting RH, Demopoulos A, DeAngelis LM. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology. 2004;63:901–903
  60. Correa DD, DeAngelis LM, Shi W. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology. 2004;62:548–555
  61. Lai R, Abrey LE, Rosenblum MK. Treatment-induced leukoencephalopathy in primary CNS lymphoma: A clinical and autopsy study. Neurology. 2004;62:451–456
  62. Thiessen B, DeAngelis LM. Hydrocephalus in radiation leukoencephalopathy: Results of ventriculoperitoneal shunting. Arch Neurol. 1998;55:705–710

PII: S1053-4296(07)00019-7

doi: 10.1016/j.semradonc.2007.02.008

Seminars in Radiation Oncology
Volume 17, Issue 3 , Pages 223-229 , July 2007

Article Tools

* Image Usage & Resolution